Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › VK2735

VK2735

GIP/GLP-1 · s.c. / oral · Viking Therapeutics

Data cut 12 November 2026 · page built 16 November 2026 · 5 trial arms · 2 trials with results · 4 registered trials · see on the pipeline board

Summary

Also known as
Viking Therapeutics
Mechanism
GIP/GLP-1
Route
s.c. / oral
Company
Viking Therapeutics
Highest development stage
phase 3
Status (as of data cut)
Phase 3: s.c. VANQUISH-1/-2 (since 2025); oral SUNRISE-1/-2 started Oct 2026 (obesity with and without T2D); VENTURE s.c. phase 2 published (Obesity 2026) verify
Next milestone
VANQUISH readouts; SUNRISE enrolment

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingVANQUISH phase 3 ongoingVANQUISH 1
T2D2 phase 3 ongoingVANQUISH 2 ongoingVANQUISH 2
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
VENTURE (phase 2, s.c.)VK2735 5.0 mg weeklyobesity1335−10.9 % vs −1.7 %
Δ −9.2 pp
—−0.3 vs +0.011.0 vs 0.011.0 vs 14.046.0 vs 20.017.0 vs 0.06.0 vs 3.0−6.7 vs −4.2verified
VENTURE (phase 2, s.c.)VK2735 10 mg weeklyobesity1336−12.9 % vs −1.7 %
Δ −11.2 pp
—−0.3 vs +0.011.0 vs 0.014.0 vs 14.037.0 vs 20.017.0 vs 0.06.0 vs 3.0−7.0 vs −4.2verified
VENTURE (phase 2, s.c.)VK2735 15 mg weeklyobesity1335−14.7 % vs −1.7 %
Δ −13.0 pp
—−0.4 vs +0.020.0 vs 0.020.0 vs 14.063.0 vs 20.029.0 vs 0.03.0 vs 3.0−11.0 vs −4.2verified
VENTURE-Oral (phase 2)oral VK2735 90 mg dailyobesity1340——−11.1 % vs −1.3 %
estimand not specified
——25.0 vs 18.0————verified
VENTURE-Oral (phase 2)oral VK2735 120 mg dailyobesity1340——−12.2 % vs −1.3 %
estimand not specified
——38.0 vs 18.0————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (28)
  • VK2735 5.0 mg weekly · weight_eff · Table 2
    LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
  • VK2735 5.0 mg weekly · ae_dc · Table 3
    TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
  • VK2735 5.0 mg weekly · disc_any · Table 3
    Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
  • VK2735 5.0 mg weekly · nausea · Table 3
    Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
  • VK2735 5.0 mg weekly · vomiting · Table 3
    Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
  • VK2735 5.0 mg weekly · sae · Table 3
    TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
  • VK2735 5.0 mg weekly · hba1c · Table 5, Hemoglobin A1c
    Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
  • VK2735 5.0 mg weekly · sbp · Table 5, Systolic blood pressure
    Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
  • VK2735 10 mg weekly · weight_eff · Table 2
    LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
  • VK2735 10 mg weekly · ae_dc · Table 3
    TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
  • VK2735 10 mg weekly · disc_any · Table 3
    Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
  • VK2735 10 mg weekly · nausea · Table 3
    Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
  • VK2735 10 mg weekly · vomiting · Table 3
    Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
  • VK2735 10 mg weekly · sae · Table 3
    TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
  • VK2735 10 mg weekly · hba1c · Table 5, Hemoglobin A1c
    Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
  • VK2735 10 mg weekly · sbp · Table 5, Systolic blood pressure
    Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
  • VK2735 15 mg weekly · weight_eff · Table 2
    LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
  • VK2735 15 mg weekly · ae_dc · Table 3
    TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
  • VK2735 15 mg weekly · disc_any · Table 3
    Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
  • VK2735 15 mg weekly · nausea · Table 3
    Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
  • VK2735 15 mg weekly · vomiting · Table 3
    Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
  • VK2735 15 mg weekly · sae · Table 3
    TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
  • VK2735 15 mg weekly · hba1c · Table 5, Hemoglobin A1c
    Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
  • VK2735 15 mg weekly · sbp · Table 5, Systolic blood pressure
    Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
  • oral VK2735 90 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
    Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
  • oral VK2735 90 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
    Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %
  • oral VK2735 120 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
    Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
  • oral VK2735 120 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
    Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %

Registered trials (4)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
SUNRISE 1
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
ObesityPhase 3not yet recruiting2026-11 → 2028-07560not yet recruitingNCT07868835
SUNRISE 2
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
ObesityPhase 3not yet recruiting2026-11 → 2028-10560not yet recruitingNCT07868939
VANQUISH 2
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
ObesityPhase 3active not recruiting2025-06 → 2027-071100active not recruitingNCT07104383
VANQUISH 1
VK2735 for Weight Management Phase 3
ObesityPhase 3active not recruiting2025-06 → 2027-074500active not recruitingNCT07104500

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: VK2735. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/vk2735/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.